NCT04307173View on ClinicalTrials.gov

Study of Multiple Ascending Dose of KBL693 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

November 12, 2020

Conditions
Moderate to Severe Asthma
Interventions
DRUG

KBL693

"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"

DRUG

KBL693

"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"

Trial Locations (1)

6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

KoBioLabs
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

KoBioLabs

INDUSTRY

NCT04307173 - Study of Multiple Ascending Dose of KBL693 in Healthy Participants | Biotech Hunter | Biotech Hunter